Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 184

Year

2023 19

2022 16

2021 23

2020 5

2019 17

2018 13

2017 6

2016 13

2015 9

2014 8

2013 8

2012 13

2011 7

2010 7

2009 10

2008 1

2007 2

2000 2

open ︾

Keywords

cancer 27

lung cancer 16

breast cancer 8

cervical cancer 8

cancer therapy 7

Cancer 5

Colorectal cancer 5

targeted therapy 5

prostate cancer 4

COVID-19 3

Diagnosis 3

cancer immunotherapy 3

drug resistance 3

immunotherapy 3

Artificial intelligence 2

Breast cancer 2

DNA methylation 2

Exosomes 2

Glycosylation 2

open ︾

Search scope:

排序： Display mode:

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine

Hongmei Xu, Xuetao Cao

Frontiers of Medicine 2011, Volume 5, Issue 4, Pages 323-332 doi: 10.1007/s11684-011-0172-4

Abstract:

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: Immunotherapy plays a compelling role in cancer treatment and has already made remarkable progress.developed, such as small molecules, bispecific antibodies, chimeric antigen receptor T cell products, and cancervaccines.Chimeric antigen receptor T cell products and cancer vaccines have also been investigated.

Keywords： cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancervaccines

HTML PDF Collect

Developing effective tumor vaccines: basis, challenges and perspectives

XU Qingwen, CHEN Weifeng

Frontiers of Medicine 2007, Volume 1, Issue 1, Pages 11-19 doi: 10.1007/s11684-007-0003-9

Abstract: Among these antigens, cancer/testis antigen (CT antigen) is considered to be the most promising targetContinued progress in development of effective cancer vaccines depends on the identification of appropriate

Keywords： development conventional identification elucidation Successful immunotherapy

HTML PDF Collect

Coronavirus Variants—Will New mRNA Vaccines Meet the Challenge?

Jennifer Welsh

Engineering 2021, Volume 7, Issue 6, Pages 712-714 doi: 10.1016/j.eng.2021.04.005

HTML PDF Collect

Universal influenza virus vaccines: what can we learn from the human immune response following exposure

Daniel Stadlbauer, Raffael Nachbagauer, Philip Meade, Florian Krammer

Frontiers of Medicine 2017, Volume 11, Issue 4, Pages 471-479 doi: 10.1007/s11684-017-0602-z

Abstract: Typically, these vaccines induce responses that target group 1 or group 2 hemagglutinins with little

Keywords： universal influenza virus vaccine hemagglutinin stalk H7N9

HTML PDF Collect

Development Trends and Suggestions of Nucleic Acid Vaccines

Li Aihua, Yang Xuemei, Sun Yinan, Yuan Yakun, Yang Juntao

Strategic Study of CAE 2021, Volume 23, Issue 4, Pages 153-161 doi: 10.15302/J-SSCAE-2021.04.018

Abstract: This article first summarizes the R&D status of nucleic acid vaccines from the aspects of related19 outbreak on the mRNA vaccine research, summarizes the main fields of application of nucleic acid vaccinesFurthermore, we suggest that the key technologies of nucleic acid vaccines should be developed by improvingMoreover, the safety and efficacy of nucleic acid vaccines should be strictly monitored; stakeholdersresearch on mRNA vaccine technologies that have safety risks and potentially disruptive effects on cancer

Keywords： ribonucleic acid (RNA) vaccine messenger RNA (mRNA) vaccine coronavirus disease 2019 (COVID-19) cancer

HTML PDF Collect

A review of the safety and efficacy of current COVID-19 vaccines

Frontiers of Medicine 2022, Volume 16, Issue 1, Pages 39-55 doi: 10.1007/s11684-021-0893-y

Abstract: The rapid development of effective COVID-19 vaccines is an extraordinary achievement.reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressed COVID-19 vaccinesOverall, most of the current vaccines have shown safety and efficacy/effectiveness during actual clinicalHowever, many challenges are faced by pandemic control in terms of maximizing the effect of vaccines,

Keywords： COVID-19 SARS-CoV-2 vaccine safety efficacy effectiveness immunogenicity

HTML PDF Collect

Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 942-942 doi: 10.1007/s11684-021-0876-z

HTML PDF Collect

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and inthyroid cancer, but also increasingly in various types of cancers at low rates.

Keywords： pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug

HTML PDF Collect

Epithelial-to-mesenchymal transition in cancer: complexity and opportunities

Yun Zhang, Robert A. Weinberg

Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 361-373 doi: 10.1007/s11684-018-0656-6

Abstract: termed the epithelial-to-mesenchymal transition (EMT) plays an important role in both development and cancerinvasiveness, drug-resistance and the ability to form metastases at distant organs, and thereby contribute to cancer

Keywords： epithelial-to-mesenchymal transition cancer metastasis cancer stem cell

HTML PDF Collect

Metformin for cancer prevention

Yonghua Yang

Frontiers of Medicine 2011, Volume 5, Issue 2, Pages 115-117 doi: 10.1007/s11684-011-0112-3

HTML PDF Collect

Orlistat induces ferroptosis-like cell death of lung cancer cells

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 922-932 doi: 10.1007/s11684-020-0804-7

Abstract: synthesis is involved in the progression and treatment resistance of many types of cancers, including lung cancer; however, targeting the lipogenetic pathways for cancer therapy remains an unmet clinical need.we tested the anticancer activity of orlistat, an FDA-approved anti-obesity drug, in human and mouse cancerand we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lung cancerand other types of cancer.

Keywords： orlistat ferroptosis FAF2 lung cancer

HTML PDF Collect

Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance

Fung Zhao, Eric W.-F. Lam

Frontiers of Medicine 2012, Volume 6, Issue 4, Pages 376-380 doi: 10.1007/s11684-012-0228-0

Abstract:

The forkhead transcription factors FOXO and FOXM1 have pivotal roles in tumorigenesis and in mediating chemotherapy sensitivity and resistance. Recent research shows that the forkhead transcription factor FOXM1 is a direct transcriptional target repressed by the forkhead protein FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling pathway. Intriguingly, FOXM1 and FOXO3a also compete for binding to the same gene targets, which have a role in chemotherapeutic drug action and sensitivity. An understanding of the role and regulation of the FOXO-FOXM1 axis will impact directly on our knowledge of chemotherapeutic drug action and resistance in patients, and provide new insights into the design of novel therapeutic strategy and reliable biomarkers for prediction of drug sensitivity.

Keywords： FOXO3a FOXM1 transcription factor cancer drug resistance tumorigenesis

HTML PDF Collect

Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic

Frontiers of Medicine doi: 10.1007/s11684-023-1050-6

Abstract: Pancreatic cancer, notorious for its late diagnosis and aggressive progression, poses a substantial challengeThis review endeavors to furnish a holistic insight into pancreatic cancer, encompassing its epidemiologyand explore recent research advancements in precursor lesions and molecular subtypes of pancreatic cancerAdditionally, we highlight the development and application of multi-omics approaches in pancreatic cancerresearch and discuss the latest combinations of pancreatic cancer biomarkers and their efficacy.

Keywords： pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy